impact factor



Maintenance treatment of ANCA-associated vasculitides



  1. Department of Internal Medicine, Referral Centre for Rare Systemic and Autoimmune Diseases, Vasculitis and Scleroderma, Hôpital Cochin, APHP, Université Paris Descartes, Paris, France.

2017 Vol.35, N°1 ,Suppl.103
PI 0199, PF 0201

Free to view
(click on article PDF icon to read the article)

PMID: 28406765 [PubMed]

Received: 29/03/2017
Accepted : 30/03/2017
In Press: 05/04/2017
Published: 20/04/2017


ANCA-associated vasculitis(AAV) covers a group of systemic necrotising vasculitides characterised by inflammation of small vessels, sometimes with granuloma, and associated with autoantibodies to neutrophil cytoplasmic proteases (proteinase-3 or myeloperoxidase). Potentially lethal if not promptly diagnosed and treated, AAV in most patients can be induced into remission with the current treatment modalities. However, the risk of relapse remains high, necessitating prolonged immunosuppressive or immunomodulating maintenance therapy, whose optimal duration remains undetermined. Herein, we review only maintenance treatments for AAVs.

Rheumatology Article